Trend of Non-contrast Chest Computed Tomography Use in the Lung Cancer Screening Era: SEER-Medicare 2008–2016

This is a preview of subscription content, access via your institution.

Figure 1
Figure 2


  1. 1.

    Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5): 395-409.

    Article  PubMed  Google Scholar 

  2. 2.

    Moyer VA. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 160(5): 330-8.

    Article  PubMed  Google Scholar 

  3. 3.

    Centers for Medicare & Medicaid Services. Medicare coverage of screening for lung cancer with low dose computed tomography (LDCT). Assessed February 2, 2020.

  4. 4.

    Jemal A, Fedewa SA. Lung cancer screening with low-dose computed tomography in the United States-2010 to 2015. JAMA Oncol. 2017; 3(9): 1278-81.

    Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Pinsky PF, Gierada DS, Black W, Munden R, Nath H, Aberle D, et al. Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment. Ann Intern Med. 2015; 162(7): 485-91.

    Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    The American College of Radiology, Radiological Society of North America, American Society of Radiological Technologists and American Association of Physicists in Medicine. 2020 Image Wisely: Pledge for Referring Practitioners. Available at: Accessed November 16, 2020.

Download references


The collection of the California cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract N01-PC-35136 awarded to the Northern California Cancer Center, contract N01-PC-35139 awarded to the University of Southern California, and contract N02-PC-15105 awarded to the Public Health Institute; and the Centers for Disease Control and Prevention’s National Program of Cancer Registries, under agreement #U55/CCR921930-02 awarded to the Public Health Institute. The authors of this report are responsible for its content. The ideas and opinions expressed herein are those of the authors and endorsement by the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred. The authors acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database. The interpretation and reporting of the SEER-Medicare data are the sole responsibility of the authors.


Dr. Yang reports grants from the Ministry of Science and Technology (MOST108-2918-I-006-006) and National Cheng Kung University Hospital (NCKUH-11002029) during the conduct of the study. Dr. Gross reports grants from Johnson & Johnson, NCCN Foundation (Pfizer/AstraZeneca), Flatiron Health, and Genentech outside the submitted work. Dr. S.Y. Wang reports grants from Genentech outside the submitted work. No other disclosures were reported.

Author information




All authors had access to the data and a role in writing the manuscript.

Corresponding author

Correspondence to Shi-Yi Wang MD, PhD.

Ethics declarations

Conflict of Interest

The authors declare that they do not have a conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yang, SC., Gross, C., Wang, JD. et al. Trend of Non-contrast Chest Computed Tomography Use in the Lung Cancer Screening Era: SEER-Medicare 2008–2016. J GEN INTERN MED (2021).

Download citation